UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney disease by treating secondary hyperoxaluria, announced that its compelling investment opportunity was recognized by conference attendees casting their votes for the company in the Innovation Challenge. The votes cast for Oxidien placed the company in the top three in the impressive line-up of companies at the recent Redefining Early Stage Investments (RESI) virtual conference. Oxidien was also a finalist in the Women In Bio (WIB) sponsored live pitch that took place at the Digital RESI conference in June 2020.
“We are very pleased to be in the top three in the Innovation Challenge. This placement was by participants’ vote, which speaks to the compelling investment opportunity and value evident to all those who voted for us,” said Helena Cowley, CEO of Oxidien Pharmaceuticals. “It was an additional pleasure to participate in the Women In Bio live pitch session among very impressive female founders and CEOs. We are committed to realizing additional value for our current and future shareholders and are inviting more investors to join us as we prepare for our Phase 2 study.”Learn more about Oxidien Pharmaceuticals Receives High Recognition at RESI Conference in Partnership With Women in Bio.